Cancer Communications
indexed by SCI
BMC

doi: 10.5732/cjc.011.10186
MicroRNA therapeutics: principles, expectations, and challenges
Rajesha Rupaimoole, Hee-Dong Han, Gabriel Lopez-Berestein, Anil K. Sood
Department of Gynecologic Oncology The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. asood@ mdanderson.org
[Abstract] MicroRNAs (miRNAs) are a class of highly abundant non-coding RNA molecules that are involved in several biological processes. Many miRNAs are often deregulated in several diseases including cancer. There is substantial interest in exploiting miRNAs for therapeutic applications. In this editorial, we briefly review current advances in the use of miRNAs or antisense oligonucleotides (antagomirs) for such therapies. One of the key issues related to therapy using miRNAs is degradation of naked particles in vivo. To overcome this limitation, delivery systems for miRNA-based therapeutic agents have been developed, which hold tremendous potential for improving therapeutic outcome of cancer patients.
Chinese Journal of Cancer 2011, Volume: 30, Issue 6, Page: 368-370
[ PDF Full-text ]
[Google Scholar]


Cite this article

Rajesha Rupaimoole, Hee-Dong Han, Gabriel Lopez-Berestein, Anil K. Sood. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011, 30(6):368-370. doi:10.5732/cjc.011.10186


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China